# L-type calcium channel blockers at therapeutic concentrations are not linked to CRAC channels and heart failure

## TL;DR

This study confirms that amlodipine, a common blood pressure medication, does not activate CRAC channels at therapeutic doses, supporting its continued use.

## Contribution

The study provides evidence that amlodipine does not increase heart failure risk via CRAC channel activation at therapeutic concentrations.

## Key findings

- Amlodipine does not activate CRAC channels at concentrations used in therapy.
- Findings support the safety of amlodipine in hypertension treatment.
- Results align with a previous meta-analysis on amlodipine's safety profile.

## Abstract

Amlodipine has been used as a front-line anti-hypertensive therapy for decades by virtue of blocking voltage-operated calcium channels with high affinity and specificity. Recently, the safety of amlodipine has been questioned, as it was reported to activate Ca2+ release-activated Ca2+ (CRAC) channels and increase the risk of heart failure. Here we show, using a variety of approaches, that amlodipine does not activate CRAC channels at therapeutic concentrations. Combined with our previous meta-analysis, our study should reassure physicians that amlodipine should continue to be prescribed for treating hypertension.